Center for Scientific Review; Notice of Closed Meeting, 68181 [2022-24713]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 218 / Monday, November 14, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Charter Renewal for the Advisory
Committee on Heritable Disorders in
Newborns and Children
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act
(FACA) and the Public Health Service
(PHS) Act, HHS is hereby giving notice
that the Advisory Committee on
Heritable Disorders in Newborns and
Children (ACHDNC) has been renewed.
The effective date of the charter renewal
is November 10, 2022.
FOR FURTHER INFORMATION CONTACT:
Soohyun Kim, Acting Designated
Federal Official, Maternal and Child
Health Bureau, HRSA, 5600 Fishers
Lane, 18N38A, Rockville, Maryland
20857; 301–594–4202; or skim@
hrsa.gov.
SUPPLEMENTARY INFORMATION: The
ACHDNC provides advice and
recommendations to the Secretary of
HHS (Secretary) on policy, program
development, and other matters of
significance concerning the activities
under section 1111 of the PHS Act (42
U.S.C. 300b–10). The ACHDNC is also
governed by the provisions of the
FACA, as amended (5 U.S.C. App.),
which sets forth standards for the
formation and use of advisory
committees. The ACHDNC advises the
Secretary on the development of
newborn screening activities,
technologies, policies, guidelines, and
programs for effectively reducing
morbidity and mortality in newborns
and children having, or at risk for,
heritable disorders. The ACHDNC
reviews and reports regularly on
newborn and childhood screening
practices, recommends improvements in
the national newborn and childhood
screening programs, and fulfills
requirements stated in the authorizing
legislation. In addition, the ACHDNC’s
recommendations regarding inclusion of
additional conditions for screening on
the Recommended Uniform Screening
Panel, following adoption by the
Secretary, are evidence-informed
preventive health services provided for
in the comprehensive guidelines
supported by HRSA pursuant to section
2713 of the PHS Act (42 U.S.C. 300gg–
13). Under this provision, nongrandfathered group health plans and
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:30 Nov 10, 2022
Jkt 259001
68181
health insurance issuers offering nongrandfathered group or individual
health insurance are required to provide
insurance coverage without cost-sharing
(a co-payment, co-insurance, or
deductible) for preventive services for
plan years (i.e., policy years) beginning
on or after the date that is 1 year from
the Secretary’s adoption of the
condition for screening. The charter
renewal for the ACHDNC was approved
on November 4, 2022. The filing date for
the ACHDNC charter renewal is
November 10, 2022. Renewal of the
ACHDNC charter gives authorization for
the committee to operate until
November 10, 2024.
A copy of the ACHDNC charter is
available on the ACHDNC website at
https://www.hrsa.gov/advisorycommittees/heritable-disorders/
index.html. A copy of the charter also
can be obtained by accessing the FACA
database that is maintained by the
Committee Management Secretariat
under the General Services
Administration. The website address for
the FACA database is https://
www.facadatabase.gov/.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive Bethesda,
MD 20892, (Virtual Meeting).
Contact Person: Jonathan Arias, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7840, Bethesda, MD 20892, 301–435–
2406 ariasj@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Maria G. Button,
Director, Executive Secretariat.
National Cancer Institute; Notice of
Closed Meeting
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24713 Filed 11–10–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2022–24674 Filed 11–10–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel High-End
and Shared Instrumentation Grants.
Date: November 15, 2022.
Time: 2:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; OCT2022
Cycle 42 NExT SEP Committee Meeting.
Date: December 7, 2022.
Time: 10:00 a.m. to 3:00 p.m.
E:\FR\FM\14NON1.SGM
14NON1
]]>Agencies
[Federal Register Volume 87, Number 218 (Monday, November 14, 2022)]
[Notices]
[Page 68181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24713]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel High-End and Shared Instrumentation Grants.
Date: November 15, 2022.
Time: 2:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Jonathan Arias, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170, MSC 7840, Bethesda, MD
20892, 301-435-2406 [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-24713 Filed 11-10-22; 8:45 am]
BILLING CODE 4140-01-P
